IGF1R and neoplasm: Given that hyper-activation of IGFIR has been observed in NSCLC patient specimens [29] and disruption of IGFIR signaling with monoclonal antibodies or small molecules inhibits tumor growth in vivo [30,31], a better understanding of the molecular features of this model is warranted.